Welcome to our dedicated page for Seer news (Ticker: SEER), a resource for investors and traders seeking the latest updates and insights on Seer stock.
Seer, Inc., a prominent player in the life sciences sector, is revolutionizing the field of proteomics. The company is known for its development and commercialization of the Proteograph Product Suite, an integrated solution designed to unlock deep, unbiased biological information. The suite comprises consumables, automation instrumentation, and software that enable comprehensive proteomic profiling and sample analysis, providing researchers with a detailed view of the proteome.
Seer's technology is built around proprietary engineered nanoparticles, which offer unmatched depth and scale in proteomic studies. This innovative approach allows for the detection of over 6,000 proteins and more than 55,000 peptide IDs in complex samples, such as plasma. The Proteograph Product Suite is designed for ease of use, with features like minimal hands-on time and fully automated workflows, making it accessible to a wide range of research labs.
The company primarily targets academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies, offering its products for non-diagnostic and non-clinical purposes. Seer has established significant collaborations with industry leaders like Discovery Life Sciences, Bruker Scientific LLC, and Thermo Electron North America LLC, enhancing its market reach and technological capabilities.
Recently, Seer has made headlines through its partnership with Panome Bio to integrate deep, unbiased proteomics with metabolomics, aiming to accelerate research in biomarker discovery and drug development. The collaboration is expected to facilitate groundbreaking studies with robust pathway analyses, significantly advancing the understanding of biology and disease.
In another noteworthy development, Seer announced a major study published in Nature Communications, conducted in collaboration with Weill Cornell Medicine. This research showcased Seer's Proteograph workflow's potential to unveil novel proteogenomic insights, linking genetic variation with protein abundance at peptide level resolution. This study is a testament to Seer's commitment to advancing multi-omics research and enhancing precision medicine.
Seer's financial outlook remains optimistic despite macroeconomic challenges. The company continues to drive the adoption of its Proteograph Product Suite by expanding its Technology Access Center and increasing its commercial reach. As more customer data and third-party publications highlight the power of Seer's technology, the company anticipates growing adoption and impact in the scientific community.
In summary, Seer, Inc. is at the forefront of proteomics, offering transformative solutions that provide unparalleled insights into the proteome, thus paving the way for significant advancements in biological research and precision medicine.
Seer, a life sciences company specializing in proteomics, announced participation in the Cowen 43rd Annual Health Care Conference in Boston, MA, on March 8, 2023. The company’s management will engage in a fireside chat and Q&A session at 9:50 a.m. Eastern Time. Investors can access the live webcast via Seer's website, with an archived replay available post-conference. Seer’s innovative Proteograph Product Suite facilitates deep proteomic analysis efficiently and is designed for laboratory use. This suite is not intended for diagnostic procedures and aims to enhance research capabilities in proteomics.
Seer, Inc. (Nasdaq: SEER) will report its financial results for Q4 and full year 2022 on March 2, 2023, after market close. A conference call will be held at 1:30 p.m. PT / 4:30 p.m. ET, available via webcast on the Investor section of Seer’s website. Seer specializes in proteomics, offering the Proteograph Product Suite, which enables deep, unbiased proteomic analysis efficiently. This solution uses proprietary engineered nanoparticles and is designed for use in a variety of laboratory settings.
Seer, Inc. (Nasdaq: SEER) announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023. Management will present at 3:00 p.m. PT / 6:00 p.m. ET, followed by a Q&A session. Investors can access a live webcast on the Investor section of Seer's website, with an archived replay available afterwards.
Seer specializes in proteomics, offering the Proteograph™ Product Suite, a unique solution for deep proteomic analysis. For further details, visit www.seer.bio.
Discovery Life Sciences has launched a new Proteomic Services Division, accepting samples from various research entities to enhance drug and diagnostic development. This division integrates cutting-edge technologies, including the Seer Proteograph Product Suite and SCIEX LC-MS/MS systems. Discovery has formed a Proteogenomics Consortium with Seer and SCIEX to advance plasma proteomic studies, aimed at uncovering novel biomarkers. The company also highlighted its status as the largest certified provider for Olink's Proximity Extension Assay platform in the Americas.
Seer, Inc. (Nasdaq: SEER) reported Q3 2022 revenue of $4.0 million, up from $2.2 million in Q3 2021, mainly due to increased sales of the Proteograph Product Suite. The gross profit was $1.9 million with a gross margin of 49%. Operating expenses rose to $27.0 million, leading to a net loss of $24.0 million, compared to a loss of $18.4 million in the previous year. Seer maintains a full-year revenue guidance of $14.0 million to $16.0 million.
Seer, Inc. (NASDAQ: SEER) will report its Q3 2022 financial results on November 8, 2022, at 1:30 p.m. PT. The conference call will be available via webcast on Seer's investor website, with a replay posted afterward. Seer specializes in developing innovative proteomics solutions through its Proteograph Product Suite, designed for quick and comprehensive analysis. This offering aims to enhance laboratory efficiency and accessibility.
Seer, a life sciences company based in Redwood City, California, announced its participation in the Morgan Stanley Global Healthcare Conference in New York City on September 13, 2022. Management will partake in a fireside chat at 8:35 a.m. Eastern Time. The session will be available via a live webcast on the company's investor website, with an archived replay to follow. Seer specializes in proteomics, offering the Proteograph Product Suite for deep proteomic analysis, designed for research use only.
Seer, Inc. announced the publication of a study demonstrating advancements in its Proteograph Product Suite for comprehensive proteomic analysis. The study, published in Advanced Materials, highlights the integration of proteomics methods, nanoengineering, and machine learning to capture thousands of proteins and discover novel biomarkers. CEO Omid Farokhzad emphasized the technology's capacity for deep interrogation of the proteome, enhancing research capabilities globally. The Proteograph suite combines engineered nanoparticles and software for rapid, scalable proteomics.
Seer, Inc. (Nasdaq: SEER) reported a revenue increase to $3.6 million for Q2 2022, up from $1.3 million in Q2 2021, driven by sales of the Proteograph Product Suite. The Proteograph™ Analysis Suite 2.0 was launched, enhancing their competitive edge in proteogenomics. However, the net loss for the quarter widened to $22.8 million compared to $16.6 million in the prior year. Operating expenses grew to $25.0 million, influenced by employee costs and facility expansions. The company maintains a full-year revenue guidance of $14.0 million to $16.0 million.
FAQ
What is the current stock price of Seer (SEER)?
What is the market cap of Seer (SEER)?
What is Seer, Inc. known for?
What does the Proteograph Product Suite include?
Who are Seer's primary customers?
What recent collaborations has Seer announced?
What are the benefits of Seer's proprietary engineered nanoparticles?
What was the focus of Seer's recent study published in Nature Communications?
What is Seer's strategy to drive adoption of its technology?
Is the Proteograph Product Suite intended for diagnostic use?
Where is Seer, Inc. headquartered?
What potential does Seer see in its technology?
